Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy.
Haggai Bar-YosephN LevharL SelingerU ManorM YavzoriO PicardE FudimUri KopylovR EliakimS Ben-HorinY ChowersBella UngarPublished in: Alimentary pharmacology & therapeutics (2017)
Infliximab levels below 6.8 μg/mL and antibodies to infliximab levels above 4.3 μg/mL-eq before the second infusion are associated with primary nonresponse, especially among Crohn's disease patients.